Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Gross Profit (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Gross Profit for 13 consecutive years, with $167.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 6.35% year-over-year to $167.5 million, compared with a TTM value of $546.0 million through Dec 2025, up 11.53%, and an annual FY2025 reading of $546.0 million, up 11.53% over the prior year.
  • Gross Profit was $167.5 million for Q4 2025 at Tandem Diabetes Care, up from $134.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $167.5 million in Q4 2025 and bottomed at $73.3 million in Q1 2021.
  • Average Gross Profit over 5 years is $109.6 million, with a median of $103.2 million recorded in 2022.
  • The sharpest move saw Gross Profit skyrocketed 69.98% in 2021, then decreased 19.24% in 2023.
  • Year by year, Gross Profit stood at $113.7 million in 2021, then rose by 1.58% to $115.5 million in 2022, then fell by 19.24% to $93.3 million in 2023, then surged by 68.77% to $157.5 million in 2024, then rose by 6.35% to $167.5 million in 2025.
  • Business Quant data shows Gross Profit for TNDM at $167.5 million in Q4 2025, $134.3 million in Q3 2025, and $125.9 million in Q2 2025.